Mutations related to the RTK‐RAS pathway (NF1) were most common in patients with situ recurrent GBM, while mutations in the MUC family and TP53 pathway (MUC16, CHEK2) were prevalent and continuously increased in patients with non‐in situ recurrent GBM. Here, CHEK2 is linked to glioblastoma.